Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The first immunotherapy has been approved by the FDA for the treatment of hormone-resistant prostate cancer.

Sipuleucel-T Suspension for Intravenous Infusion (Provenge®